Literature DB >> 18088201

Assessment and treatment of suicide risk in schizophrenia.

Maurizio Pompili1, David Lester, Marco Innamorati, Roberto Tatarelli, Paolo Girardi.   

Abstract

Schizophrenic patients at risk of suicide are more likely to be young, male, white, never married, with post-psychotic depression, and a history of substance abuse and suicide attempts. Hopelessness, social isolation, awareness of illness and hospitalization are also related to suicide risk. Deteriorating health with a high level of premorbid functioning, recent loss or rejection, limited external support, family stress or instability are other features that have been reported in schizophrenic patients who commit suicide. Atypical antipsychotics, especially clozapine, have emerged as important tools in the therapeutic armamentarium. Psychosocial intervention and psychotherapy may play an important role in the management of suicide risk, especially if such interventions help the patient face daily difficulties, loneliness and conflicts inside the family.

Entities:  

Mesh:

Year:  2008        PMID: 18088201     DOI: 10.1586/14737175.8.1.51

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  11 in total

1.  A comparison of correlates of suicidal ideation prior to initial hospitalization for first-episode psychosis with prior research on correlates of suicide attempts prior to initial treatment seeking.

Authors:  Peggy Flanagan; Michael T Compton
Journal:  Early Interv Psychiatry       Date:  2011-12-13       Impact factor: 2.732

Review 2.  Crowdsourcing for conducting randomized trials of internet delivered interventions in people with serious mental illness: A systematic review.

Authors:  John A Naslund; Kelly A Aschbrenner; Lisa A Marsch; Gregory J McHugo; Stephen J Bartels
Journal:  Contemp Clin Trials       Date:  2015-07-16       Impact factor: 2.226

Review 3.  Emerging mHealth and eHealth interventions for serious mental illness: a review of the literature.

Authors:  John A Naslund; Lisa A Marsch; Gregory J McHugo; Stephen J Bartels
Journal:  J Ment Health       Date:  2015-05-28

4.  Is poor premorbid functioning a risk factor for suicide attempts in first-admission psychosis?

Authors:  Shelly Bakst; Jonathan Rabinowitz; Evelyn J Bromet
Journal:  Schizophr Res       Date:  2009-12-01       Impact factor: 4.939

5.  Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension.

Authors:  Amresh Shrivastava; Megan E Johnston; Nilesh Shah; Marco Innamorati; Larry Stitt; Meghana Thakar; David Lester; Maurizio Pompili
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

6.  The future of mental health care: peer-to-peer support and social media.

Authors:  J A Naslund; K A Aschbrenner; L A Marsch; S J Bartels
Journal:  Epidemiol Psychiatr Sci       Date:  2016-01-08       Impact factor: 6.892

7.  PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain.

Authors:  Shweta Hegde; Hao Ji; David Oliver; Neema S Patel; Nicolas Poupore; Michael Shtutman; Michy P Kelly
Journal:  Neuroscience       Date:  2016-08-17       Impact factor: 3.590

8.  Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics.

Authors:  Maurizio Pompili
Journal:  Front Psychiatry       Date:  2020-01-14       Impact factor: 4.157

9.  Risk assessment and suicide by patients with schizophrenia in secondary mental healthcare: a case-control study.

Authors:  Javier-David Lopez-Morinigo; Rosa Ayesa-Arriola; Beatriz Torres-Romano; Andrea C Fernandes; Hitesh Shetty; Matthew Broadbent; Maria-Encarnacion Dominguez-Ballesteros; Robert Stewart; Anthony S David; Rina Dutta
Journal:  BMJ Open       Date:  2016-09-27       Impact factor: 2.692

10.  Suicide attempts and related factors in schizophrenia patients.

Authors:  Memduha Aydın; Bilge C Ilhan; Rukiye Tekdemir; Yusuf Çokünlü; Vefa Erbasan; Kürşat Altınbaş
Journal:  Saudi Med J       Date:  2019-05       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.